Tianjin Medical University General Hospital
🇨🇳China
Clinical Trials
64
Active:1
Completed:18
Trial Phases
5 Phases
Early Phase 1:1
Phase 1:7
Phase 2:16
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (52 trials with phase data)• Click on a phase to view related trials
Not Applicable
26 (50.0%)Phase 2
16 (30.8%)Phase 1
7 (13.5%)Phase 4
2 (3.8%)Early Phase 1
1 (1.9%)Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Phase 1
Recruiting
- Conditions
- Chronic Inflammatory Demyelinating PolyradiculoneuropathyNMO Spectrum DisorderMyasthenia GravisIdiopathic Inflammatory Myopathies
- Interventions
- Drug: BAFF-R CART
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT07022197
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lobectomy
Phase 4
Not yet recruiting
- Conditions
- Chronic Postsurgical Pain
- Interventions
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 320
- Registration Number
- NCT07018375
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Phase 1
Recruiting
- Conditions
- Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)AML (Acute Myelogenous Leukemia)B-ALLMyeloma MultipleT-lymphocyte LymphomaT-ALL/Lymphoma
- Interventions
- Drug: CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06911710
- Locations
- 🇨🇳
TianJin China. TianJin Medical University General, TianJin, Tianjin, China
Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes
Not Applicable
Recruiting
- Conditions
- Monogenic Diabetes
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT06746610
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
Eculizumab for Acute Attack of Neuromyelitis Optica Spectrum Disorder
Phase 2
Not yet recruiting
- Conditions
- Neuromyelitis Optica Spectrum Disorder Attack
- Interventions
- Drug: IVMPDrug: Complement protein C5 inhibitor
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT06673394
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
News
Statins Show 39% Mortality Reduction in Sepsis Patients, Large Study Reveals
A major study analyzing over 265,000 sepsis patients found that statin treatment was associated with a 39% lower 28-day mortality rate compared to standard care alone.